The European Commission granted marketing authorization for Invega, an atypical antipsychotic medication for the treatment of schizophrenia. This once-daily medication is specifically designed to deliver paliperidone—the drug’s active ingredient—through the osmotic delivery system (OROS). In clinical trials, Invega demonstrated significant efficacy controlling the symptoms of schizophrenia compared to placebo and was generally well tolerated. Invega is the first treatment for schizophrenia...